B
BioOrbit
Biotech & Life Sciences · London, United Kingdom · Founded 2023
BioOrbit is space manufacturing company developing hardware for the large-scale crystallisation of protein drugs MoreLess
BioOrbit is a UK-based company specializing in the manufacturing of pharmaceuticals in space. The company focuses on the large-scale crystallization of proteins for monoclonal antibodies (mAbs), with the aim of producing more effective cancer drugs.
By leveraging the microgravity environment of space, BioOrbit intends to overcome some of the limitations of Earth-based pharmaceutical manufacturing. The company is preparing for pre-clinical trials in 2026 for protein crystals produced in its planned orbital factory. The primary market for BioOrbit's products is the pharmaceutical industry, which is constantly seeking to develop more effective treatments for a variety of diseases, including cancer.
The company's business model is centered on research and development, with the ultimate goal of commercializing its space-manufactured pharmaceuticals. This involves securing partnerships with pharmaceutical companies and research institutions to further develop and test its products.
Keywords: pharmaceutical manufacturing, space technology, protein crystallization, monoclonal antibodies, cancer drugs, orbital factory, pre-clinical trials, space-based research, drug development, biotechnology.
Company overview
BioOrbit company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2023
- Headquarters
- London, United Kingdom
- Employees
- 20
- Open positions
- 2
- Dealroom signal
- 84.5
Valuation & funding
BioOrbit funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Apr 2026 | $13M | $52M | 7percent Ventures · Seedcamp · Type One Ventures · Auxxo Female Catalyst Fund | ↗ |
| GRANT✓Other financing | Feb 2026 | $330K | — | Government of the United Kingdom | ↗ |
| SEED✓Equity / VC | May 2024 | $0 | — | 7percent Ventures | — |
| SUPPORT PROGRAM✓Other financing | Nov 2023 | $0 | — | ESA Business Incubation Centre United Kingdom | ↗ |
| SUPPORT PROGRAM✓Other financing | Oct 2023 | $0 | — | Seraphim Space | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 20 |
| 2025 | 14 |
| 2024 | 10 |
| 2023 | 5 |
Growth signals
BioOrbit website traffic
Latest recorded traffic for BioOrbit is 960 monthly website visits, down 54.3% over the last three months. BioOrbit's team grew 42.9% over the past year.
Hiring
Open positions at BioOrbit
Current openings linked to this company in Dealroom.
Comparisons
BioOrbit compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
BioOrbit's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where BioOrbit has talent and traffic
team presence
In the news
Latest news about BioOrbit
Recent press, funding announcements, and product moves mentioning BioOrbit — open to read from the original sources.
Market sentiment
What the market is saying about BioOrbit
An AI-synthesized read of the highest-engagement posts about BioOrbit on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioOrbit’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.